NASDAQ:ICPT Intercept Pharmaceuticals (ICPT) Stock Forecast, Price & News $10.48 -0.32 (-2.96%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$9.85▼$10.7450-Day Range$9.99▼$11.8652-Week Range$8.82▼$21.86Volume1.31 million shsAverage Volume892,724 shsMarket Capitalization$437.85 millionP/E Ratio1.64Dividend YieldN/APrice Target$22.36 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intercept Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside113.4% Upside$22.36 Price TargetShort InterestBearish29.02% of Float Sold ShortDividend StrengthN/ASustainability-2.13Upright™ Environmental ScoreNews Sentiment0.30Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.06) to $2.27 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector493rd out of 963 stocksPharmaceutical Preparations Industry226th out of 458 stocks 3.3 Analyst's Opinion Consensus RatingIntercept Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.36, Intercept Pharmaceuticals has a forecasted upside of 113.4% from its current price of $10.48.Amount of Analyst CoverageIntercept Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.02% of the float of Intercept Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIntercept Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Intercept Pharmaceuticals has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntercept Pharmaceuticals does not currently pay a dividend.Dividend GrowthIntercept Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Intercept Pharmaceuticals is -2.13. Previous Next 1.8 News and Social Media Coverage News SentimentIntercept Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Intercept Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ICPT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Intercept Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.Percentage Held by Institutions83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.06) to $2.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intercept Pharmaceuticals is 1.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Intercept Pharmaceuticals is 1.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 99.71.Price to Book Value per Share RatioIntercept Pharmaceuticals has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intercept Pharmaceuticals (NASDAQ:ICPT) StockIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.Read More ICPT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICPT Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comZacks Research Weighs in on Intercept Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ICPT)September 21, 2023 | americanbankingnews.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 21, 2023 | americanbankingnews.comFY2025 EPS Estimates for Intercept Pharmaceuticals, Inc. Raised by Zacks Research (NASDAQ:ICPT)September 20, 2023 | americanbankingnews.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Sees Significant Growth in Short InterestSeptember 9, 2023 | markets.businessinsider.comIntercept Pharma (ICPT) Receives a Hold from RBC CapitalSeptember 8, 2023 | finance.yahoo.comWhy CymaBay Therapeutics Stock Is Jumping TodaySeptember 7, 2023 | finance.yahoo.comWhy Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?September 24, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.September 1, 2023 | finance.yahoo.comWhy Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?August 4, 2023 | msn.comCanaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Buy RecommendationAugust 2, 2023 | finanznachrichten.deIntercept Pharmaceuticals, Inc.: Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 2, 2023 | finance.yahoo.comIntercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 2, 2023 | finance.yahoo.comIntercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/YJuly 26, 2023 | finance.yahoo.comIntercept to Announce Second Quarter 2023 Financial Results on August 2, 2023July 26, 2023 | finance.yahoo.comIntercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?July 13, 2023 | msn.comHC Wainwright & Co. Upgrades Intercept Pharmaceuticals (ICPT)July 13, 2023 | markets.businessinsider.comIntercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC BusinessJuly 13, 2023 | msn.comIntercept Pharma gains on H.C. Wainwright double upgradeJuly 13, 2023 | markets.businessinsider.comPositive Report for Intercept Pharma (ICPT) from H.C. WainwrightJuly 11, 2023 | markets.businessinsider.comRBC Capital Keeps Their Hold Rating on Intercept Pharma (ICPT)July 6, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Decreased by 24.23% to 14.62June 29, 2023 | finance.yahoo.comBiotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More UpdatesJune 26, 2023 | msn.comRBC Capital Maintains Intercept Pharmaceuticals (ICPT) Sector Perform RecommendationJune 26, 2023 | finance.yahoo.comIntercept (ICPT) to Restructure Operations, Cut WorkforceJune 26, 2023 | markets.businessinsider.comBank of America Securities Reaffirms Their Sell Rating on Intercept Pharma (ICPT)June 24, 2023 | markets.businessinsider.comIntercept Pharma To Cut JobsSee More Headlines Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ICPT Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ICPT CUSIP45845P10 CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees341Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.36 High Stock Price Forecast$54.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+113.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$6.39 Trailing P/E Ratio1.64 Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins68.07% Pretax Margin-51.82% Return on Equity-189.98% Return on Assets-30.32% Debt Debt-to-Equity Ratio3.31 Current Ratio2.52 Quick Ratio2.52 Sales & Book Value Annual Sales$285.71 million Price / Sales1.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book4.66Miscellaneous Outstanding Shares41,780,000Free Float39,192,000Market Cap$437.85 million OptionableOptionable Beta1.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Jerome B. Durso (Age 55)Pres, CEO & Director Comp: $1.37MMr. Andrew Saik (Age 54)Chief Financial Officer Comp: $888.6kMr. Jared M. Freedberg J.D. (Age 55)Gen. Counsel Comp: $812.55kMs. Linda M. Richardson (Age 59)Exec. VP & Chief Commercial Officer Comp: $837.73kDr. M. Michelle Berrey M.D. (Age 56)M.P.H., MPH., Pres of R&D and Chief Medical Officer Comp: $1.12MMr. Rocco Venezia (Age 47)Chief Accounting Officer & Treasurer Mr. Nareg SagherianExec. Director of Global Investor RelationsMr. David Ford (Age 53)Chief HR Officer Dr. Mark Pruzanski M.D. (Age 55)Founder, Advisor & Director Paul NitschmannSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMEmergent BioSolutionsNYSE:EBSRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInstitutional OwnershipBarclays PLCBought 97,427 shares on 9/21/2023Ownership: 0.513%Wolverine Trading LLCSold 2,200 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 56,000 shares on 8/22/2023Ownership: 0.134%Citadel Advisors LLCBought 300 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaSold 5,413 shares on 8/15/2023Ownership: 0.007%View All Institutional Transactions ICPT Stock - Frequently Asked Questions Should I buy or sell Intercept Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ICPT shares. View ICPT analyst ratings or view top-rated stocks. What is Intercept Pharmaceuticals' stock price forecast for 2023? 8 Wall Street analysts have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $13.00 to $54.00. On average, they anticipate the company's stock price to reach $22.36 in the next year. This suggests a possible upside of 113.4% from the stock's current price. View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts. How have ICPT shares performed in 2023? Intercept Pharmaceuticals' stock was trading at $12.37 on January 1st, 2023. Since then, ICPT shares have decreased by 15.3% and is now trading at $10.48. View the best growth stocks for 2023 here. Are investors shorting Intercept Pharmaceuticals? Intercept Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 10,400,000 shares, an increase of 9.2% from the August 15th total of 9,520,000 shares. Based on an average daily trading volume, of 986,900 shares, the days-to-cover ratio is currently 10.5 days. Currently, 29.0% of the company's stock are short sold. View Intercept Pharmaceuticals' Short Interest. When is Intercept Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our ICPT earnings forecast. How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company earned $83.70 million during the quarter, compared to analyst estimates of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 189.98% and a net margin of 68.07%. Intercept Pharmaceuticals's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.68) EPS. What ETF holds Intercept Pharmaceuticals' stock ? Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio. What guidance has Intercept Pharmaceuticals issued on next quarter's earnings? Intercept Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $320.00 million-$340.00 million, compared to the consensus revenue estimate of $320.39 million. What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO? 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib). What is Intercept Pharmaceuticals' stock symbol? Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT." Who are Intercept Pharmaceuticals' major shareholders? Intercept Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.52%), State Street Corp (10.01%), Renaissance Technologies LLC (2.10%), Boothbay Fund Management LLC (0.00%), Rockefeller Capital Management L.P. (1.86%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Sandip Kapadia and Srinivas Akkaraju. View institutional ownership trends. How do I buy shares of Intercept Pharmaceuticals? Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intercept Pharmaceuticals' stock price today? One share of ICPT stock can currently be purchased for approximately $10.48. How much money does Intercept Pharmaceuticals make? Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $437.85 million and generates $285.71 million in revenue each year. The biopharmaceutical company earns $221.82 million in net income (profit) each year or $6.39 on an earnings per share basis. How many employees does Intercept Pharmaceuticals have? The company employs 341 workers across the globe. How can I contact Intercept Pharmaceuticals? Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001. This page (NASDAQ:ICPT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.